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Abstract: The molecular and cellular processes leading to aortic aneurysm development in Marfan
syndrome (MFS) remain poorly understood. In this study, we examined the changes of aortic cell
populations and gene expression in MFS by performing single-cell RNA sequencing (scRNA seq) on
ascending aortic aneurysm tissues from patients with MFS (n = 3) and age-matched non-aneurysmal
control tissues from cardiac donors and recipients (n = 4). The expression of key molecules was
confirmed by immunostaining. We detected diverse populations of smooth muscle cells (SMCs),
fibroblasts, and endothelial cells (ECs) in the aortic wall. Aortic tissues from MFS showed alterations
of cell populations with increased de-differentiated proliferative SMCs compared to controls. Furthermore, there was a downregulation of MYOCD and MYH11 in SMCs, and an upregulation of
COL1A1/2 in fibroblasts in MFS samples compared to controls. We also examined TGF-β signaling,
an important pathway in aortic homeostasis. We found that TGFB1 was significantly upregulated in
two fibroblast clusters in MFS tissues. However, TGF-β receptor genes (predominantly TGFBR2) and
SMAD genes were downregulated in SMCs, fibroblasts, and ECs in MFS, indicating impairment in
TGF-β signaling. In conclusion, despite upregulation of TGFB1, the rest of the canonical TGF-β pathway and mature SMCs were consistently downregulated in MFS, indicating a potential compromise
of TGF-β signaling and lack of stimulus for SMC differentiation.
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Marfan syndrome (MFS), an autosomal dominant disease, is associated with aortic
aneurysms predominantly involving the aortic root [1]. MFS is caused by mutations in
the gene encoding the glycoprotein fibrillin-1 (FNB1) [2], which are believed to disrupt
cell signaling and vascular integrity [3,4]. Patients with MFS have altered smooth muscle
cell (SMC) phenotypes. Studies have indicated changes in the expression of contractile
and extracellular matrix (ECM) genes [5,6] and alterations in SMC appearance [7]. New
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sequencing technologies, such as single-cell RNA (scRNA) sequencing, have provided a
more precise understanding of the range of SMC phenotypes [8].
We used scRNA sequencing to better understand the non-immune cell populations in
the aortic wall in MFS. Here, we focused on non-immune cells because they are in direct
contact with fibrilin-1 and are the predominant permanent cells forming the aortic wall,
making them likely drivers of aortic pathology in MFS. We hypothesized that, compared
with control cells, non-immune cells in aneurysmal tissue from patients with MFS would
show changes in phenotype and cell-specific gene expression that are detectable by singlecell transcriptome analysis.
2. Materials and Methods
2.1. Human Tissue Samples
The protocol for collecting human tissue samples was approved by the institutional
review board at Baylor College of Medicine. Written informed consent was provided by
all subjects or their legal representatives before enrollment. All experiments conducted
with human tissue samples were performed in accordance with the relevant guidelines and
regulations and conformed to the principles outlined by the Declaration of Helsinki.
Diseased tissue samples were obtained from patients (Supplementary Table S1) with
advanced aortic root and ascending aortic aneurysms (without dissection) who were
diagnosed with MFS according to the revised Ghent criteria, which do not require a known
mutation of FBN1 for diagnosis. We excluded patients taking angiotensin II receptor
blockers and those with other genetic conditions related to aortopathy, such as bicuspid
aortic valve, and patients with ascending aortic dissection, aortitis, or active infection. For
controls, non-aneurysmal ascending aortic tissue samples were obtained from age-matched
heart transplant donors and recipients. Total sample number for all single-cell experiments
was 4 controls and 3 patients with MFS. The median age was 38 years (range, 23–40 years)
for MFS patients and 41 years (range, 23–47 years) for controls.
2.2. Antibodies
The TGF-β antibody (#3709), TGF-β receptor II antibody (#41896), Phopho-SMAD2
(Ser465/Ser467) antibody (#18338), SMAD2 antibody (#5339), and cyclin D1 (#2978) antibody were obtained from Cell Signaling. The α-smooth muscle Actin (ab89989) antibody
was purchased from Abcam.
2.3. Tissue Processing
Before processing, pieces of unfixed aortic tissue were cut and embedded in optimal
cutting temperature (OCT) compound for immunofluorescence staining. For single-cell
analysis, each sample was placed on ice, and a 1–2 cm piece of aortic tissue was separated
into adventitial, medial, and intimal layers and minced into small pieces in Hank’s balanced
salt solution (HBSS) (without Ca2+ and Mg2+ ) with 10% FBS. The tissue was placed in an
enzyme cocktail prepared with 3 mg/mL collagenase type II, 0.15 mg/mL collagenase type
XI, 0.25 mg/mL soybean trypsin inhibitor, 0.1875 mg/mL elastase lyophilized, 0.24 mg/mL
hyaluronidase type I, and 2.38 mg/mL HEPES in HBSS (with Ca2+ and Mg2+ ) and digested
in a 37 ◦ C water bath for 1–2 h depending on the tissue dissociation (confirmed microscopically). Medial tissues, because of longer digestion times, were digested separately from
the adventitial and intimal layers. A 40-µm cell strainer was used to remove debris from
the samples, and the flow-through from the medial and adventitial/intimal layers was
recombined and centrifuged at 300× g for 10 min. The pellet was re-suspended in HBSS
(without Ca2+ and Mg2+ ) with 5% FBS and incubated on ice for 30 min. Cells were stained
with DAPI, and flow cytometry was used to collect live single cells.
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2.4. Single-Cell RNA Sequencing and Raw Data Processing
Single-cell suspensions were processed in the 10× Genomics Chromium system, and 30
Gene Expression v3 Libraries were constructed and sequenced using the Illumina NovaSeq
6000 system. Raw fastq data alignment was processed by using the Cell Ranger 3.0 with
GRCh38 as the reference genome. Unique reads mapped to the reference genome were
tagged with unique molecular identifiers (UMIs), and a UMI count matrix was formed.
The remainder of the analysis was performed using R and associated packages [9–15]. The
data were processed by R package Seurat [13] with the following quality control criteria:
gene count per cell >200 and <4000 (or 5000 depending on the overall average level of
genes per cell in each sample) and percentage of mitochondria genes <10%. Additionally,
we identified a high level of HBB expression in our data set, which likely indicated red
blood cell contamination. We filtered the cells to include only those without expression
of the HBB gene. Individual sample non-immune cell data, cell counts from each sample
comprising each cluster, and quality control metrics within the non-immune cells in each
sample are shown in Supplementary Materials online, Figure S1A–C, respectively. Control
tissue contributed more SMCs to the populations and a higher feature expression/cell than
did patient tissue.
2.5. Cell Clustering and Identification
The data were normalized, scaled, and subjected to linear dimensional reduction,
clustering, and non-linear dimensional reduction for t-distributed stochastic neighbor
embedding (t-SNE) visualization as described in the Seurat vignettes. To combine multiple
datasets and ensure that no non-immune cells were missed, we extracted the UMI counts for
the non-immune cells from each sample and recombined them by using a resolution of 0.6.
Conserved (marker) genes for each cluster were identified by the function “FindAllMarkers”
in Seurat [13]. The general cell type of each non-immune cell cluster was further identified
using known markers. Feature expression per cluster and overall expression in MFS
compared to control tissues are shown in Supplementary Figure S2.
2.6. Differential Gene Analysis and Function Annotation
Differential gene expression within each cluster between MFS and control samples
was determined using WaVE-EdgeR [16–18]. Differential gene expression between groups
of cells (e.g., SMCs) and overall differential gene expression between MFS and control
samples were identified using the “Find Markers” function in Seurat [19].
2.7. Module (Composite) Score
The module score for a particular list of genes expressed in each cluster was calculated
by using the function “AddModuleScore” in Seurat. To avoid bias by selecting only certain
genes, we compiled set lists (e.g., all collagen or all integrin genes) for use in the cluster
analyses. All genes in each list were used in the module score unless they were not
expressed in any clusters.
2.8. Correlation Analysis
To identify genes correlating with a particular gene, we performed a correlation
analysis for the gene of interest within each cluster of interest using Spearman’s correlation
in R.
2.9. Immunofluorescence
OCT-embedded aortic sections were sliced into 5-µm sections onto slides. Tissues were
fixed with BD Cytofix/Cytoperm (BD Biosciences, San Jose, CA, USA) and permeabilized
with 1× BD Perm/Wash (BD Biosciences). Nonspecific staining was reduced by blocking
with 10% donkey serum for 1 h. The sections or cells were then incubated with primary
antibody at 4 ◦ C overnight, washed with 1× BD Perm/Wash, and incubated with secondary
antibody. Antibodies used for immunostaining are listed in Supplementary Table S2. Nuclei
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were counterstained with 4’,6-diamidino-2-phenylindole (DAPI). The slides were mounted
with ProLongTM Diamond Antifade Mountant with DAPI (Life Technologies, Corporation,
Eugene, OR, USA). Sections incubated with secondary antibody alone served as negative
controls. Fluorescence microscopy at 10× and 20× was performed (Leica microscope,
Leica Microsystems Inc., Buffalo Grove, IL, USA) using the same exposure times for each
wavelength across all samples. Fiji/ImageJ [20,21] imaging was used to quantify three
different areas for each staining of each sample (three controls, three patients with MFS).
For dual antibody staining, co-localization was identified as falling within a set yellow
threshold (red/green overlap), the bounds of which were kept constant throughout the
sample analyses. Proliferative SMCs (identified by co-localization of CCND1 and SM22α)
were quantified by multiplying the total area of colocalization by the mean brightness value.
Representative images were taken from the samples that provided the median values on
immunofluorescence quantification. Confocal microscopy was performed using the Leica
SP5 confocal microscope.
3. Results
3.1. Overall Cell Populations and Non-Immune Cells in the Aortic Wall
To create a comprehensive catalog of cell clusters, we first combined the data from
MFS (n = 3) and control (n = 4) samples (Figure 1A). We identified major cell groups
in the aortic wall by using known markers (Supplementary Material online, Figure S3)
for SMCs (SMTN, MYH11), fibroblasts (collagen genes, LUM, DCN), endothelial cells
(ECs) (PECAM11, POSTN, VWF), monocytes and macrophages (CD14, CD68), CD8 T cells
(CD8A, CD8B), natural killer cells (KLRC1), and mast cells (CPA3 and TPSB2). Cluster 16
was consistent for both CD8 T cells and natural killer cells and was left unnamed in this
analysis.
Samples were evaluated independently using the Seurat package in R, and nonimmune cells in each sample were extracted and re-combined (Figure 1B), showing 18
clusters. Supplementary Figure S3B shows the expression of well-known markers within
each cluster. Six clusters highly expressing contractile genes, namely ACTA2, TAGLN,
CALD1, TPM2, MYH11, SMTN, CNN1, and MYOCD, were classified as SMC-like. Three
clusters highly expressing ECM component genes, including LTBP2, TNFRSF11B, CYTL1,
COL6A1, COL1A1, COL1A2, COL5A1, LTBP1, BGN, and FN1, were classified as fibroblasts.
We classified three clusters highly expressing PECAM11, POSTN and VWF as ECs. Two
clusters highly expressing THY1, PDGFRB, and RERGL and genes involved in angiogenesis
and remodeling, such as VEGFA, NOTCH3, ADAMTS1, and FABP4, were classified as
mesenchymal stem cells (MSCs), alternatively named pericytes in other studies [22].
Additionally, we identified two small clusters highly expressing genes associated with
immune cells (MHC-II genes, complement-factor genes, CD68, CD69, and CD96). Gene
expression patterns within these clusters showed macrophage-like and T-cell-like clusters.
3.2. Heterogeneous SMC Population in the Aortic Wall
Further analysis was conducted within SMC clusters of the combined MFS and control
samples to determine SMC phenotype (Supplementary Figure S4).
3.2.1. Mature Contractile and Contractile SMCs
Within these clusters, we first identified SMCs with the most traditional contractile
phenotype using known markers of differentiated contractile SMCs [23]. We calculated
a composite score of average RNA expression of SMTN, MYH11, and CNN1 in each of
the SMC and fibroblast clusters (Supplementary Figure S4A). The cluster with the highest
expression of these markers was identified as the mature contractile SMC cluster. The
phenotypes of other SMC clusters were identified by calculating the differential gene
expression between each SMC-like cluster and the mature contractile SMC cluster (Supplementary Figure S4B). One cluster was similar to the mature contractile SMC cluster with
few comparatively upregulated or downregulated genes. This cluster expressed high levels
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contractile genes but had a slightly decreased expression of maturity markers, including
SMTN and CNN1, and was named contractile SMCs.
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3.2.3. Fibromyocytes and Intermediate SMCs
One cluster expressed both contractile and ECM genes (Supplementary Material
online, Figure S4C) but was more closely related to the other SMCs on correlation analysis
(Supplementary Figure S4D). This cluster highly expressed TNFSRF11B (Supplementary
Figure S4E), which encodes osteoprotegerin, a tumor necrosis factor receptor involved
in vascular calcification [25]. This increased expression correlates with a similar cluster
of modulated SMCs described by Wirka and colleagues [22], termed fibromyocytes to
emphasize differentiation from a SMC rather than fibroblast lineage. Another cluster also
highly expressed TNSFRF11B and genes involved in ECM structures (ELN, FN1, VCAN,
KRT1) and angiogenesis (ENG). This cluster, classified as intermediate SMCs, expressed
higher levels of contractile genes than fibromyocytes.
3.2.4. De-Differentiated, Proliferative SMCs
Finally, one cluster had moderate levels of contractile genes (MYH11) and fibroblast
genes (CYTL1) and increased expression of cyclin genes (predominately cyclin D) (Supplementary Figure S4F). Despite a relatively low overall gene expression compared to
other clusters (Supplementary Figure S2A), the presence of this cluster in each sample
(Supplementary Figure S1A) after applying quality control metrics and excluding cells
expressing the contaminant HBB supports a true SMC cluster, rather than a cluster due
to technical processing. Compared with other SMCs, this cluster had relatively increased
expression of THY1, a stem cell marker, and increased inflammatory and endothelial markers (Supplementary Figure S4G,H). This supported a de-differentiated, proliferative SMC
phenotype.
3.3. Fibroblast Phenotypes in the Aortic Wall
Next, we identified differentially expressed genes (DEGs) between each fibroblast
cluster and the other two fibroblast clusters (Supplementary Figure S5A).
3.3.1. Stressed Fibroblasts
Similar to our findings with SMCs, one cluster of fibroblasts had increased expression of genes involved in the stress response (CXCL2, CXCL3, and IER3) and a higher
stress response module score of ATF3, JUN, JUNB, FOS, and FOSB (Supplementary Figure
S5B). This cluster, called stressed fibroblasts, likely reflects the technical artifacts of tissue
processing.
3.3.2. Quiescent Fibroblasts
One fibroblast cluster had increased expression of genes associated with ECM maintenance and genes involved in fibroblast quiescence [26,27], including complement factors
C1R and C1S and ECM genes LUM and DCN. These cells also expressed increased levels of
SERPINF1, an angiogenesis inhibitor [28]. This was consistent with quiescent fibroblasts,
which synthesize and maintain the ECM but can be stimulated to re-enter the cell cycle
to proliferate and promote healing. The quiescent fibroblasts had increased composite
scores for genes involved in ECM remodeling including matrix metalloproteinases and A
Disintegrin and Metalloprotease with Thrombospondin motifs (ADAMTS genes) (Supplementary Figure S5C). Several enzymes in these groups have been linked to aortic aneurysm
development. Previously, we showed that ADAMTS-4 contributes to sporadic ascending
aortic aneurysm development in mice [29].
3.3.3. Activated Fibroblasts
The final fibroblast cluster had increased expression of genes involved in SMC contraction (MYL9, TAGLN, and ACTA2) and blood vessel development (NOTCH3, THBS2,
COL18A1, IGFB5, IGFBP5, PDGFRB, and TIMP1). Activated fibroblasts differed from fibromyocytes. Activated fibroblasts expressed fewer contractile markers than fibromyocytes
(Supplementary Figure S4A) and were closely related to other fibroblasts on correlation
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analysis (Supplementary Figure S4D). This cluster was consistent with activated fibroblasts, which represent proliferative fibroblasts that secrete collagen and pro-angiogenesis
molecules in response to vascular injury [28,30–32]. Consistent with this proliferative and
healing phenotype, activated fibroblasts had the highest composite scores of cyclin D genes,
collagen genes, contractile genes, chemokine genes, and integrin genes when compared
to other fibroblasts (Supplementary Figure S5D). The expression of NOTCH3, a receptor
gene involved in SMC differentiation and blood vessel development [19,33], was highest
in activated fibroblasts when all fibroblasts and SMCs were compared (Supplementary
Figure S5E).
3.4. Endothelial Cells and MSCs in the Aortic Wall
We identified three clusters of ECs and calculated DEGs between them (Supplementary
Figure S6A). The largest EC cluster expressed increased POSTN (periostin) and quiescence
markers, including IL33 and CDKN1A, and was highest in expressing genes involved in
innate immune responses. Together, this indicates a baseline EC population. However,
these cells showed the same upregulation of stress response genes, such as ATF3, JUN,
JUNB, FOS, and FOSB, seen in SMCs and fibroblasts as indicated in the composite score
(Supplementary Figure S6B). This increased expression of stress genes is likely due to tissue
processing. Overall, this cluster likely represents an artificial stress response in a normal
EC population.
The second largest EC cluster showed increased expression of genes involved in
angiogenesis (FLT1, DLL4, NOTCH4, CAV1, and EGFL7) and increased composite scores
of type IV collagen genes (the predominant collagen in basement membrane), integrin
genes, and remodeling genes (Supplementary Figure S6C). This cluster also had the highest
expression of genes involved in tight and adherens junctions (Supplementary Figure S5D),
suggesting involvement in maintaining the endothelial barrier. Together, these expression
patterns suggest a more activated EC type, which we named healing ECs to encompass the
relatively increased expression of genes involved in angiogenesis, collagen deposition, and
remodeling.
The smallest cluster had increased expression of coagulation pathway genes and
an increased composite score of gap junction genes (Supplementary Figure S6E). The
expression of genes encoding type I collagen, contractile proteins, and cyclin D1 was higher
in this cluster (Supplementary Figure S6F), which was named de-differentiated ECs.
The two clusters of MSCs had increased expression of genes involved in angiogenesis
and remodeling compared with other non-immune cells (Supplementary Figure S6G,H).
One cluster had a higher expression of THY1 and collagen genes (Supplementary Figure
S6I,J) and was termed healing MSCs. The other exhibited higher expression of the contractile gene MYH11 (Supplementary Figure S6K) and was named contractile MSCs. These
two clusters may represent mesenchymal cells moving towards either a fibroblast-like,
ECM-producing phenotype, or a contractile, SMC-like phenotype.
3.5. Immune-like Non-Immune Cells in the Aortic Wall
Despite removing immune cells from the individual samples, when non-immune
samples were recombined, we identified two small clusters predominantly expressing
genes associated with immune cells (Supplementary Figure S7A). One was macrophagelike with high expression of MHC-II genes and CD14 and CD68. The other was T-cell-like
with high expression of CD8A and CD69. These cells were not initially “captured” as
immune cells in the overall data, likely due to the higher expression of non-immune cell
genes than their true immune cell counterparts, and may represent cells of an immune-cell
lineage that move toward a non-immune cell phenotype. Similar to SMCs, both immunelike clusters had moderate collagen I and III expression (Supplementary Figure S7B).
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3.6. Phenotypic Continuum of SMCs and Fibroblasts
Changes in gene expression between fibroblasts and SMCs indicate a spectrum of
phenotypes rather than distinct subsets. The feature plots in Figure 1C highlight the graduated transition between cell types with markers of SMC maturity (CNN1) and fibroblast
maturity (DCN) expressed on either end of the continuum and markers of proliferation
(CCND1), intermediate SMCs/fibrocytes (TNFRSF11B), and non-specific SMCs (ACTA2)
expressed in the middle. The inverse relationship of the collagen I and contractile genes is
represented by the expression levels of COL1A2 and MYH11 across the fibroblast and SMCs
clusters in Figure 1D with the roughly equivalent expression of both genes corresponding
to peak expression of TNFRSF11B in the fibromyocytes.
3.7. Decreased SMC Differentiation in MFS
Cell distribution in the non-immune cell population was evaluated within MFS and
control tissue (Figure 2A). In MFS tissue, the largest proportion of cells was found in the
de-differentiated, proliferative SMC cluster (Figure 2B), whereas this cluster was much
smaller in control tissue. Consistent with the single-cell analysis, immunofluorescence
studies showed increased numbers of SMCs expressing higher levels of CCND1 in MFS
tissues (Figure 2C,D).
The differential expression of genes involved in SMC contraction is shown in Figure 3A.
ACTA2 was upregulated in SMCs in patients with MFS compared to control samples in
the intermediate SMC, fibromyocyte, stressed SMC, de-differentiated proliferative SMC,
and contractile SMC clusters. SMTN was upregulated in intermediate SMCs, and CNN1
was upregulated in MFS in both the intermediate SMC and fibromyocyte clusters. MYH11
was downregulated in SMCs in MFS compared to control samples in the fibromyocyte,
de-differentiated proliferative SMC, contractile SMC, and mature contractile SMC clusters.
MYOCD, a gene encoding a transcription factor that regulates multiple genes in the mature
contractile SMC phenotype, was also downregulated in SMCs in MFS samples in the
contractile SMC and mature contractile SMC clusters.
In the differential expression of genes involved in the ECM, FBN1, mutations in which
cause MFS, was significantly downregulated in MFS compared to control samples in the
quiescent fibroblast, healing MSC, mature contractile SMC, and activated fibroblast clusters
(Figure 3B). Other structural genes, including DCN, FN1, and FBLN1, were also downregulated. Downregulation of many genes involved in ECM structure was consistently
seen in activated fibroblasts of MFS samples. In contrast, genes encoding collagen I, collagen III, and elastin were upregulated in MFS versus control tissues, predominantly in
fibromyocytes and quiescent fibroblasts.
3.8. Cell-Specific Expression of Canonical TGF-β Pathways among Non-Immune Cell Populations
We studied the TGF-β pathway in depth because it drives SMC differentiation and
is of particular interest in MFS [34]. Normally, fibrillin-1 binds and sequesters the latent
TGF-β complex in the ECM. Mutations in FBN1 have been hypothesized to prevent this
sequestration and increase the bioavailability of TGF-β, affecting cell proliferation and
matrix deposition [35]. A list of genes involved in the TGF-β pathway was compiled
using previously studied genes [36] and the most specific genes in GO enrichment pathways [37,38]. Expression patterns and composite scores of TGF-β ligand genes (Figure 4A)
and receptor genes (Figure 4B) were evaluated.
Within the TGF-β ligands, TGFB1 was the most highly expressed in our dataset and
was predominantly expressed in activated fibroblasts, healing ECs, and fibromyocytes.
We saw consistently higher expression of bone morphogenetic protein (BMP) genes in EC
clusters. When TGF-β receptor gene profiles were evaluated across all non-immune clusters,
TGFBR2 was the most highly expressed receptor and was predominantly expressed in ECs,
but was present in nearly every non-immune cell cluster. SMCs additionally expressed
higher levels of TGFBR1, BMPR1A, and BMPR1B, whereas fibroblasts expressed most
receptor types.
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Figure 3. Decreased SMC differentiation in MFS compared to control. (A) Differential expression of
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In the differential expression of genes involved in the ECM, FBN1, mutations in
which cause MFS, was significantly downregulated in MFS compared to control samples
in the quiescent fibroblast, healing MSC, mature contractile SMC, and activated fibroblast
clusters (Figure 3B). Other structural genes, including DCN, FN1, and FBLN1, were also
downregulated. Downregulation of many genes involved in ECM structure was consistently seen in activated fibroblasts of MFS samples. In contrast, genes encoding collagen I,
collagen III, and elastin were upregulated in MFS versus control tissues, predominantly
in fibromyocytes and quiescent fibroblasts.
3.8. Cell-Specific Expression of Canonical TGF-β Pathways Among Non-Immune Cell
Populations
We studied the TGF-β pathway in depth because it drives SMC differentiation and is
of particular interest in MFS [34]. Normally, fibrillin-1 binds and sequesters the latent
TGF-β complex in the ECM. Mutations in FBN1 have been hypothesized to prevent this
sequestration and increase the bioavailability of TGF-β, affecting cell proliferation and
matrix deposition [35]. A list of genes involved in the TGF-β pathway was compiled using
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In the differential expression of genes involved in the ECM, FBN1, mutations in
which cause MFS, was significantly downregulated in MFS compared to control samples
in the quiescent fibroblast, healing MSC, mature contractile SMC, and activated fibroblast
clusters (Figure 3B). Other structural genes, including DCN, FN1, and FBLN1, were also
downregulated. Downregulation of many genes involved in ECM structure was consistently seen in activated fibroblasts of MFS samples. In contrast, genes encoding collagen I,
collagen III, and elastin were upregulated in MFS versus control tissues, predominantly
in fibromyocytes and quiescent fibroblasts.
3.8. Cell-Specific Expression of Canonical TGF-β Pathways Among Non-Immune Cell
Figure 4.
4. Cell-specific
Cell-specificexpression
expressionofofgenes
genesininthe
theTGF-β
TGF-βpathway.
pathway.
Expression
patterns
and
compoPopulations
Figure
Expression
patterns
and
composite
site score
of TGF-β
(A) TGF-β
ligands
and
(B) TGF-β
receptors
across
non-immune
cell clusters.
score
of (A)
ligands
andpathway
(B) TGF-β
across
non-immune
celldifferentiation
clusters.
We
studied
the
TGF-β
inreceptors
depth because
it drives SMC
and is

of particular interest in MFS [34]. Normally, fibrillin-1 binds and sequesters the latent
Cells expressing higher composite TGF-β ligand scores included activated fibroblasts,
TGF-β complex in the ECM. Mutations in FBN1 have been hypothesized to prevent this
healing ECs, and fibromyocytes. Cells that expressed higher TGF-β receptor scores included
sequestration
and increase
the bioavailability
TGF-β,
affecting cell
and
mature contractile
SMCs, intermediate
SMCs, of
and
fibromyocytes.
On proliferation
junctional analymatrix
deposition
[35].
A
list
of
genes
involved
in
the
TGF-β
pathway
was
compiled
using
sis of ligand-receptor pairs for TGFB1, TGFB2, and TGFB3, the highest junctional scores
previously
studied
genes [36]
and the and
mostallspecific
genes
in GO enrichment
pathways
were between
the activated
fibroblasts
EC types
(Supplementary
Material
online,
[37,38].
Expression
patterns
and
composite
scores
of
TGF-β
ligand
genes
(Figure
4A)
Figure S8A). Junctional analysis of BMP ligands and receptors revealed communication and
prereceptor
genes
(Figure
4B) were evaluated.
dominantly
from
the de-differentiated
ECs to all other non-immune cells (Supplementary

Figure S8B).
3.9. Compromised Canonical TGF-β Pathway in Non-Immune Cells in MFS
We initially combined all immune and non-immune cells in MFS and control tissue
to approximate the differential gene expression levels in an overall tissue analysis. When
all immune and non-immune cells were combined (Figure 5A), TGFB1 was significantly
upregulated in MFS compared to control tissue, whereas the TGF-β receptors and SMAD
genes were downregulated in MFS samples. We then separated the data into general clusters of SMCs, fibroblasts, and ECs (Figure 5B). Overall, the gene encoding the TGF-β ligand
TGFB1 was significantly upregulated in fibroblasts, and the TGF-β receptor genes and
SMAD genes were downregulated in SMCs, fibroblasts, and ECs in MFS tissues. Further
immunofluorescence staining showed that the TGFβ-1 was higher but TGF-β receptor
Figure 4. Cell-specific expression of genes in the TGF-β pathway. Expression patterns and compoII was lower in aneurysmal tissues in MFS compared to control samples (Figure 5C,D),
site score of (A) TGF-β ligands and (B) TGF-β receptors across non-immune cell clusters.
findings consistent with our single-cell data.
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genes were downregulated in MFS samples. We then separated the data into general clusters of SMCs, fibroblasts, and ECs (Figure 5B). Overall, the gene encoding the TGF-β ligand TGFB1 was significantly upregulated in fibroblasts, and the TGF-β receptor genes and
SMAD genes were downregulated in SMCs, fibroblasts, and ECs in MFS tissues. Further
immunofluorescence staining showed that the TGFβ-1 was higher but TGF-β receptor II
11 of 21
was lower in aneurysmal tissues in MFS compared to control samples (Figure 5C,D), findings consistent with our single-cell data.

Figure 5. Global analysis of genes involved in the TGF-β pathway. (A) Differential gene expression in
all combined immune and non-immune cells in MFS and control tissues. (B) Differential expression of
genes encoding TGF-β ligands and receptors in overall cell populations in MFS and control samples
in smooth muscle cells (SMCs), fibroblasts, and endothelial cells (ECs). Data are presented as RNA
average. (C) Immunofluorescence of TGF-β1 and TGFBR2 expression throughout tissue samples, to
mimic combined analysis in 4A. (D) Quantification of immunofluorescence results reveal increased
TGFβ-1 but decreased levels of TGF-β receptor II in MFS compared to control tissues. Quantification
was performed using unaltered images of 3 separate sections of slides from 3 controls and 3 patients
with MFS.

Cell-specific differential expression of TGF-β ligand genes within non-immune cells
was examined in MFS and control samples (Figure 6A). TGFB1 was upregulated in MFS
compared to control tissue, most predominantly in activated fibroblasts and quiescent
fibroblasts. Genes that correlated with TGFB1 in these clusters were then determined
(Supplementary Tables S3 and S4). In activated fibroblasts (Supplementary Table S3), genes
that correlated highly with TGFB1 included those for proteins involved in remodeling
(MMP11), proliferation (PTP4A3, TGFBI), angiogenesis (PLXDC1, EGFL7), ECM maintenance (SPARC), and degradation of misfolded glycoproteins (DERL3). Highly correlated
genes in quiescent fibroblasts (Supplementary Table S4) included those involved in pyroptosis (GSDMD), ERK signaling (WDR54), and transcription/translation (ZCRB1, EIF3L,
HEY1, RPL13A) in addition to TGFBI.
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in MFS, consistent with our single-cell data. Quantification was performed using unaltered images of
3 separate sections of slides from 3 controls and 3 patients with MFS. (G) Co-localization of TGFBR2
and SM22β on confocal microscopy. (H) Representative immunofluorescence images show decreased
phosphorylated SMAD2 (Ser465/Ser467, p-SMAD2) and total SMAD2 (SMAD2) in SMCs in MFS. (I),
Quantification of co-localized p-SMAD with SM22β and total SMAD2 with SM22β. Quantification
was performed using unaltered images of 3 separate sections of slides from 3 controls and 3 patients
with MFS. EC, endothelial cells; MSC, mesenchymal stem cells; SMC, smooth muscle cells.

The non-immune cell-specific expression of genes for TGF-β receptors in MFS compared to control tissue is shown in Figure 6B. Gene expression for receptors was predominantly downregulated in MFS compared to control tissue across the different clusters.
The receptor genes most consistently downregulated included TGFBR2 and BMPR2. Each
of these genes was downregulated in almost every cell cluster. On immunofluorescence,
TGF-β receptor II levels in SMCs were also decreased (Figure 6E–G), consistent with our
single-cell data.
The SMAD genes were downregulated in MFS compared to control across multiple
cell clusters (Figure 6C). SMAD5 was the most consistently downregulated gene including
in both MSC clusters and in intermediate SMCs, mature contractile SMCs, and contractile
SMCs. In the mature contractile SMC cluster, SMAD2, 3, 5, and 9 were also downregulated.
Consistently, immunofluorescence staining showed that phosphorylated SMAD2 and total
SMAD in SMCs of MFS patients were decreased in SMCs of MFS tissues (Figure 6H,I),
indicating downregulation of TGF-β signaling.
Cell-specific expression of genes involved in the control of TGF-β signaling was also
evaluated (Supplementary Figure S9). LTBP1, one of the components of the latent TGF-β
complex, was downregulated in both MSC clusters, the mature contractile SMCs, stressed
SMCs, contractile SMCs, stressed fibroblasts, fibromyocytes, activated fibroblasts, and
intermediate SMCs. LTBP2 was also downregulated in mature contractile SMCs, contractile
SMCs, stressed fibroblasts, fibromyocytes, and activated fibroblasts.
Finally, downstream targets of TGF-β signaling were evaluated (Figure 6D). COL1A1
and COL1A2 were upregulated in MFS, mostly in quiescent fibroblasts, fibromyocytes,
and stressed fibroblasts. In contrast, CTGF expression was generally decreased in SMCs
and fibroblasts. However, this difference was not statistically significant. SERPINE1 was
significantly downregulated in fibromyocytes and stressed fibroblasts and upregulated in
stressed SMCs.
3.10. Other Key Pathways in Non-Immune Cells in MFS
We evaluated the differential expression of genes involved in the non-canonical TGF-β
pathways in MFS compared to control tissues to determine whether these pathways are
activated by upregulation of TGFB1 in MFS tissues (Figure 7). We have provided a list
of genes within each pathway (Figure 7A), their general expression profiles within each
pathway (Figure 7B), and the highest expression scores of genes involved in the pathways
(Figure 7C). The ERK pathway was most highly expressed in the intermediate SMCs and
activated fibroblasts, the JNK pathway in the stressed SMCs and fibroblasts, the GTPase
pathway in the healing ECs and de-differentiated proliferative SMCs, and the PIK3/AKT
pathway in the fibroblast clusters.
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4. Discussion

Differential gene expression is shown in Figure 7D. Within the ERK pathway, ERK-1
In this study, we used the precision of single-cell analysis to compare the transcrip(MAPK3) was downregulated in MFS compared to control samples in stressed ECs. ERK-2
tome profile of the aortic wall in patients with MFS and control tissues. We aimed to better
(MAPK1) was downregulated in activated fibroblasts and mature contractile SMCs. Several
understand the factors driving aortic disease in MFS, and we hypothesized that cell-spegenes upstream of ERK, including SHC1, SOS1, and Ras (KRAS), were downregulated in
cific changes inMFS
cell across
signaling
and development
due to FBN1 mutations in MFS may lead
multiple
clusters.

Genes 2022, 13, 95

15 of 21

No genes within the JNK/p38 pathway were significantly differentially expressed in
MFS compared to controls, except for MKK3 (MAP2K3), which was downregulated in MFS
samples in stressed fibroblasts.
Within the small GTPase pathway, RHOA was downregulated in quiescent fibroblasts
and contractile MSCs and upregulated in contractile SMCs, fibromyocytes, and stressed
SMCs. Other genes involved in the GTPase pathway were downregulated in MFS compared
to control samples. CDC42 was downregulated in contractile MSCs, all ECs, contractile
SMCs, and fibromyocytes. PAK2 was downregulated across most clusters.
Finally, we evaluated the PI3K/AKT pathway. Although we previously showed that
AKT-2 plays a protective role in the aorta and identified decreased AKT-2 protein levels
in sporadic aortic aneurysm tissue [39], in the present study we found no differential
expression of AKT1 or AKT2 in SMCs or fibroblasts in MFS compared to controls. However,
we did observe changes in other genes in the pathway. AKT3 was downregulated in
stressed ECs, contractile SMCs, and mature contractile SMCs. PIK3CA, a subunit of PIK3,
was downregulated in mature contractile SMCs, and PIK3R1 was downregulated across
most SMC and fibroblast clusters.
4. Discussion
In this study, we used the precision of single-cell analysis to compare the transcriptome
profile of the aortic wall in patients with MFS and control tissues. We aimed to better
understand the factors driving aortic disease in MFS, and we hypothesized that cell-specific
changes in cell signaling and development due to FBN1 mutations in MFS may lead to
dysfunctional non-immune cells. Here, we highlighted the phenotypic continuum between
fibroblasts and SMCs in aortic wall tissue and identified an increased proportion of dedifferentiated, proliferative SMCs in MFS tissues, potentially due to a decreased response
to TGF-β in MFS compared to control tissues.
Historically, SMCs were believed to undergo a “phenotypic switch” from a contractile
phenotype to a synthetic phenotype that produced more ECM proteins. This switch
was associated with the advancement of cardiovascular disease. However, more recent
studies have supported the idea of a spectrum of SMC phenotypes rather than two distinct
groups, and this idea has been expanded with the development of single-cell analysis.
Using scRNA sequencing on coronary artery tissue, Wirka et al. identified modulated
SMCs (fibromyocytes) that showed a spectrum of ECM production with cells expressing
progressively increasing levels of ECM genes as they moved farther from traditional
contractile SMCs [22]. Pedroza et al. also identified a spectrum of SMC phenotypes using
single-cell analysis of an MFS aortic root SMC line. They found significant upregulation
of ECM genes in modulated SMCs in MFS tissue compared to control and an increased
proportion of ECM-expressing SMCs in MFS [6]. The same group later showed gradual
phenotype change across SMCs and modulated SMCs in the aortic root/ascending aorta in
aneurysmal Fbn1C1041G/+ and non-aneurysmal control mice [40].
Our data from single-cell analysis of the aortic wall support an inverse relationship
between the expression of contractile and ECM genes that is not binary but that progressively changes within cell clusters not only between SMCs, but even from quiescent
fibroblasts to mature contractile SMCs. These findings support the idea of a phenotypic
continuum encompassing multiple clusters in addition to the fibromyocytes described by
Wirka et al. [22] and align with the scRNA sequencing studies of SMCs in mice by Pedroza
et al. [6,40]. Along this continuum between fibroblasts and SMCs, we identified a cluster
of de-differentiated, proliferative SMCs that was predominantly composed of cells from
MFS tissue and was, in fact, the largest cluster in MFS tissue. Immunofluorescence studies
also supported this finding, with increased CCND1high SMCs in aneurysmal ascending
aortic tissue in patients with MFS compared to controls. This may represent a cluster of
SMCs that has either de-differentiated in response to a stimulus such as mechanical stress
or cytokine signaling or did not have the opportunity to differentiate. A modulated SMC
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cluster unique to MFS has been identified by Pedroza et al. in Fbn1C1041G/+ mice and in a
human sample [40], although whether these clusters are similar requires further analysis.
In our evaluation of contractile gene expression, ACTA2 and TAGLN were upregulated
in MFS compared to control tissue in many SMC clusters. However, MYOCD, which
encodes a transcription factor associated with vascular SMC differentiation, was downregulated in mature contractile SMCs and contractile SMCs. Additionally, we showed that
MYH11, a gene associated with a more mature contractile phenotype, was downregulated
in MFS compared to controls in mature contractile SMCs, contractile SMCs, fibromyocytes,
and de-differentiated, proliferative SMC clusters. These findings differ from those of
Pedroza et al. [6], which showed increased MYOCD and MYH11 in the aortic media in
the aortic root of MFS patients by RT-PCR and may reflect SMC-specific differential gene
expression within the aortic wall in aneurysmal disease in MFS. The discrepancy may be
due to variations in patient data, sample preparation, and gene detection and highlight the
complexity of the mechanisms underlying the diverse patterns of alterations of different
contractile genes. Further research is needed to fully understand these pathways. In evaluating genes involved in ECM maintenance within SMCs, we noted significant upregulation
of COL1A1/2 and ELN in MFS fibromyocytes, which is the cluster of modulated SMCs
moving in a fibroblast direction from a traditional contractile phenotype. When combined
with our finding of increased de-differentiated, proliferative SMCs in MFS, these results
suggest that SMCs are less differentiated toward a mature contractile phenotype in MFS
tissues than in control tissues.
Decreased differentiation of vascular SMCs to a contractile phenotype may be associated with aortic disease [41]. Although several pathways may modulate SMC differentiation, the TGF-β signaling pathway is of interest in MFS. Previous studies have
shown an increase in contractile genes, including ACTA2, MYH11, and the transcription
factor MYOCD, in MFS compared to control tissues in both whole tissue and vascular
SMC cultures [5,6]. In addition, the expression of collagen genes I and III was elevated
in both whole tissue and vascular SMC culture in tissues from patients with MFS. In one
study [5], these increases in collagen and contractile gene expression were mitigated by
pharmacological blockade of TGF-β.
Our finding of decreased expression of MYH11 and MYOCD in contractile SMCs and
increased expression of COL1A1/2 and ELN in fibroblasts and fibromyocytes in MFS tissue,
which suggests decreased SMC differentiation in MFS compared to control tissue, may
be due to the downregulation of canonical TGF-β signaling in SMCs in MFS samples. In
mature contractile SMCs, the expression of TGF-β receptors TGFBR1, TGFBR2, BMPR1A,
and BMPR2 was downregulated in MFS compared to control samples on single-cell analysis.
The expression of TGFBR2 was also downregulated across other SMC clusters in MFS
samples, including contractile SMCs, intermediate SMCs, and fibromyocytes. Decreased
levels of TGF-β receptor II in SMCs were also supported by immunofluorescence studies.
This finding implies a decreased ability of SMCs to respond to TGF-β ligands through
the canonical pathway and may indicate an overall decreased stimulus to differentiate
towards a mature contractile phenotype. Despite this downregulation of TGF-β receptors,
we did identify upregulation of TGFB1, consistent with previous studies. Total plasma
TGF-β1 in both mice and humans has been shown to be increased in MFS, and the level
of TGF-β has been associated with disease severity [35,42–45]. Additionally, TGF-β1 was
increased in aneurysmal tissue in patients with MFS [45]. In our single-cell data, when
immune and non-immune cells were combined to mimic samples for whole tissue RTPCR or immunoblotting, MFS tissue showed a higher expression of TGFB1 than control
tissue, despite downregulation of other factors in the TGF-β pathway. In evaluating the
cell-specific differential expression of genes involved in the TGF-β pathway, we found that
two particular clusters of fibroblasts mainly drive this finding: activated and quiescent
fibroblasts. This indicates that the increase in TGF-β previously described [35,42–45] is
due to an increase in transcription in aortic fibroblasts and not solely overactive signaling
secondary to dysfunctional sequestration. In fact, tissue levels of TGF-β1 identified on
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immunofluorescence were roughly equal in MFS and control samples, indicating a possible
disconnect between the increased TGFB1 RNA and its active ligand form.
Activated fibroblasts have multiple properties that suggest their importance in the
aortic wall. Their gene expression patterns indicate involvement in angiogenesis, SMC
differentiation, and immune signaling. In addition, activated fibroblasts express the highest level of NOTCH3, a gene necessary for early arterial development [19,33]. Later in
development, NOTCH3 appears to be upregulated in response to injury and to continue to
modulate SMC phenotype [19,46]. Previous studies have shown that activated fibroblasts
may be beneficial in blood vessel healing but are potentially pathologic if overly proliferative [47]. In the vascular wall adventitia, activated fibroblasts contribute to increased
release of inflammatory cytokines, resulting in recruitment of monocytes and leading to
atherosclerosis and aortic aneurysms [48]. In mice, these fibroblasts are stimulated by
angiotensin II [48]. In our study, although these activated fibroblasts were not markedly
increased in MFS compared to controls, they appeared to be highly involved in collagen
production and vascular healing after injury. Additionally, TGFB1 expression was most
highly correlated with genes associated with angiogenesis, remodeling, and proliferation.
Together, these findings indicate that activated fibroblasts play a critical role in responding
to aortic stress, suggesting the need for further study in MFS patients.
To better understand the paradoxical upregulation of TGFB1 and downregulation of
TGF-β receptors, we evaluated downstream targets of TGF-β signaling. Collagen I and III
were upregulated in MFS in quiescent fibroblasts, stressed fibroblasts, and fibromyocytes,
suggesting upregulation due to the increase in TGFB1. However, CTGF expression was
decreased (although non-significantly) in MFS samples in all SMCs and activated fibroblasts,
and SERPINE1 was either downregulated or not differentially expressed. Additionally, TGFβ receptors and downstream SMAD genes were not correspondingly upregulated. This
suggests that the upregulation of collagen may be due to activation of alternative pathways.
Collagen upregulation in the aortic media may contribute to increased arterial stiffness
and progression of aortic aneurysm [45]. Collagen deposition, particularly in the aorta
adventitia, may be a response to increased mechanical force (such as hypertension) [49].
Dysfunctional SMC elastic laminae connections caused by the FBN1 mutation may result in
altered mechanostimulation, leading to increased collagen deposition in the aortic wall [50].
Supporting this, we noted the upregulation of RHOA in several SMC clusters, which has
been shown to be involved in maintaining mechanical homeostasis [51].
One potential explanation for the paradoxical upregulation of TGFB1 without other
markers of increased TFG-β signaling is that TGFB1 gene expression does not correlate with
active TGFβ-1 protein levels. This explanation is supported by our immunofluorescence
data showing similar levels of TGFβ-1 in MFS and control tissues. It is possible that
the inactive form of the TGFβ-1 protein is produced but cannot be stored in the latent
complexes because of the FBN1 mutations and, thus, is not cleaved and activated. In our
study, downregulation of both LTBP1 and LTBP2 in SMCs, fibroblasts, and MSCs in MFS
supports the decreased formation of latent TGF-β complexes. TGF-β is released in an
inactive form and then activated once it is part of the latent TGF-β binding complexes [51].
Antibodies to LTBP1 can inhibit activation of latent TGF-β complexes [52].
We evaluated the non-canonical TGF-β pathway to determine if the upregulated
TGFB1 in MFS exerted its effect through alternative methods. TGF-β has been hypothesized
to produce different effects when activating the canonical versus the non-canonical TGFβ pathways. Loss of SMAD4, a canonical TGF-β pathway mediator, has been shown
to exacerbate the progression of thoracic aortic aneurysm and dissection in mouse MFS
models, whereas inhibition of non-canonical TGF-β signaling, mediated through ERK, JNK,
and p38, has been shown to protect against progression of thoracic aortic disease [53]. We
did not see a significant difference in the expression of most of the genes involved in the
non-canonical TGF-β pathways. This finding suggests that in advanced aneurysmal disease
in patients with MFS, neither canonical nor non-canonical TGF-β signaling is increased in
non-immune cells.
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Our study has several limitations. First, the sample size of this pilot study is small.
Additional studies with larger sample sizes are needed to confirm our findings. Additionally, most cells in the SMC clusters were from control tissues. This may be due, in
part, to decreased SMCs seen in aneurysmal tissues that have become replaced by collagen in advanced disease. We addressed this issue by comparing cluster proportions
between MFS and controls and normalizing data to cell count in each cluster. Nevertheless,
greater representation of control cells within SMC clusters may have resulted in higher
control SMC cluster resolution; thus, control data may have become the “blueprint” for
the SMC phenotypic spectrum. Although this may mask smaller differences between SMC
clusters in MFS, overall higher cell counts improve our understanding of the phenotypic
spectrum throughout the aortic wall. Future samples from MFS patients may greater
inform differences in SMC cluster distribution in MFS. Discrepancy between our single-cell
and immunofluorescence results showed the increased transcription of TGFB1 without
a marked increase in the active ligand. This finding needs further study to identify the
factors involved in this discrepancy. We acknowledge that the control tissue has a higher
expression of the early response genes shown [24] to be most affected by temperature and
processing time. This is thought to be due to differences in how the samples are obtained
and processed rather than inherent differences in the tissue of MFS patients and controls.
For this reason, we have avoided drawing conclusions based on differential expression
of these early response genes. Additionally, differences between control tissue and MFS
patient tissue may not account for sex-based differences as our patient cohort was not sex
matched. Finally, this study was conducted in patients with advanced aneurysmal disease,
and these findings may not be representative of the expression level of TGF-β pathway
genes throughout aneurysm development.
In conclusion, in a single-cell transcriptome analysis on human ascending aortic
aneurysm tissue in patients with MFS and on tissue from controls, we identified an extensive phenotypic continuum of fibroblasts and SMCs. One cluster, the de-differentiated
proliferative SMCs, was markedly increased in MFS compared to control tissue, which may
indicate changes in signaling pathways driving SMC differentiation in MFS, such as the
TGF-β pathway. Despite an upregulation of TGFB1 in fibroblast clusters in MFS, our data
support an overall decrease in canonical and non-canonical TGF-β signaling in advanced
aneurysmal disease in MFS and suggest this decrease, particularly in SMCs, may be responsible for an overall less-differentiated contractile SMC phenotype. In future studies, we
plan to identify cell populations and differential gene expression within immune cells in
MFS and to continue the enrollment of tissue samples to study sex-based differences in
aortic aneurysm development in MFS patients.
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